Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Factorial-Designed, Randomized, Double-Blind, Placebo-Controlled, Parallel- Cohort Study to Evaluate Efficacy and Safety of MELT-300 and the Contribution of Midazolam and Ketamine Components to Sedation and Intraoperative Ocular Analgesia in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

NCT05133518 is registered in ClinicalTrials.gov with Melt Pharmaceuticals as lead sponsor.

NCT NCT05133518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05133518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Factorial-Designed, Randomized, Double-Blind, Placebo-Controlled, Parallel- Cohort Study to Evaluate Efficacy and Safety of MELT-300 and the Contribution of Midazolam and Ketamine Components to Sedation and Intraoperative Ocular Analgesia in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
Lead sponsor
Melt Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
July 20, 2021
Completion date
November 3, 2022
Enrollment
338 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cataract